Welcome to our dedicated page for 60 degrees pharmaceuticals SEC filings (Ticker: SXTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug trial results, FDA correspondence, milestone payments—60 Degrees Pharmaceuticals’ SEC reports are packed with technical details that can span hundreds of pages. Locating ARAKODA revenue data or the latest trial expense for its babesiosis program inside a dense 10-K is a real challenge for investors and analysts alike.
Stock Titan solves that problem by pairing every SXTP filing with AI-powered explanations written in plain English. Need the 60 Degrees Pharmaceuticals annual report 10-K simplified? We highlight R&D spend, royalty obligations, and risk factors in seconds. Curious about cash runway between clinical phases? Our platform links directly to the relevant tables in the 60 Degrees Pharmaceuticals quarterly earnings report 10-Q filing and provides ratio analysis so you can compare quarter-over-quarter burn.
Real-time alerts ensure you never miss an update: 60 Degrees Pharmaceuticals Form 4 insider transactions real-time let you track executive stock moves before key data releases, while our dashboards flag any 60 Degrees Pharmaceuticals 8-K material events explained the moment they hit EDGAR. For deeper dives, every proxy statement comes with an at-a-glance view of 60 Degrees Pharmaceuticals proxy statement executive compensation so you can see how leadership pay aligns with pipeline progress.
- Monitor 60 Degrees Pharmaceuticals insider trading Form 4 transactions ahead of catalysts
- Get concise 60 Degrees Pharmaceuticals earnings report filing analysis without spreadsheets
- Save hours by understanding 60 Degrees Pharmaceuticals SEC documents with AI
From initial IND filings to commercialization updates, every SXTP disclosure is indexed, searchable, and translated into actionable insight—so you spend time making decisions, not reading footnotes.
60 Degrees Pharmaceuticals (SXTP) reported Q3 2025 results. Cash and cash equivalents were $4,115,779 as of September 30, 2025, up from $1,659,353 at year‑end, primarily reflecting equity financings completed in January, February, and July. Product revenue was $437,602, up from $135,293 a year ago, while research revenue was $90,960. The quarter’s net loss attributed to the company was $2,316,324, and net loss attributed to common stockholders was $2,443,191, or $0.66 per share.
Operating expenses totaled $2,316,397, including research and development of $809,777 and general and administrative of $1,506,620. An inventory reserve drove a cost of revenues increase and a gross loss of $100,088; the company recorded $436,561 of write‑downs for expired inventory in the quarter. Derivative liabilities measured at fair value were $797,275 among current liabilities totaling $2,197,394.
The company disclosed substantial doubt about its ability to continue as a going concern, citing accumulated losses and cash used in operations of $5,156,566 for the nine months. Common shares outstanding were 4,104,469 at quarter‑end and 4,230,448 as of November 13, 2025. During 2025, it raised net proceeds of $804,346, $908,627, and $4,281,300 through registered offerings, and established a $1,397,532 ATM program with no sales as of quarter‑end.
60 Degrees Pharmaceuticals, Inc. filed an 8-K announcing proposals for its upcoming shareholder meeting. Shareholders will vote on electing directors, increasing the 2022 Equity Incentive Plan by 250,000 shares, and approving an amendment to the certificate of incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10, to be set by the Board. The company also seeks ratification of RBSM LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025 and authorization to adjourn the meeting if additional proxy solicitation is needed. The filing lists these discrete corporate governance proposals without additional financial detail.
Geoffrey S. Dow, President and CEO and a director of 60 Degrees Pharmaceuticals, Inc. (SXTP), reported an open-market purchase of company common stock on September 12, 2025. He acquired 7,201 shares at a reported price of $1.3881 per share. Following the transaction, Mr. Dow directly beneficially owns 33,372 shares and indirectly beneficially owns 11,119 shares through the Geoffrey S. Dow Revocable Trust, of which he is trustee and retains voting and dispositive control.
FAQ
What is the current stock price of 60 degrees pharmaceuticals (SXTP)?
What is the market cap of 60 degrees pharmaceuticals (SXTP)?
